These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 10468294)

  • 41. Studies of interferons in the therapy of melanoma.
    Kirkwood JM
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):83-90. PubMed ID: 1948134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
    Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
    J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.
    Pehamberger H; Soyer HP; Steiner A; Kofler R; Binder M; Mischer P; Pachinger W; Auböck J; Fritsch P; Kerl H; Wolff K
    J Clin Oncol; 1998 Apr; 16(4):1425-9. PubMed ID: 9552047
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Malignant melanoma and adjuvant alpha interferon-2b for patients at high risk of relapse.
    Gale DM; Kiley KE
    Clin J Oncol Nurs; 1998 Jan; 2(1):5-10. PubMed ID: 9481250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma.
    Wong SF; Jakowatz JG; Taheri R
    Clin Ther; 2005 Dec; 27(12):1942-8. PubMed ID: 16507380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Sunbelt Melanoma Trial.
    McMasters KM
    Ann Surg Oncol; 2001 Oct; 8(9 Suppl):41S-43S. PubMed ID: 11599897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study.
    Cameron DA; Cornbleet MC; Mackie RM; Hunter JA; Gore M; Hancock B; Smyth JF;
    Br J Cancer; 2001 May; 84(9):1146-9. PubMed ID: 11379605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.
    Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG
    Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up.
    Rusciani L; Petraglia S; Alotto M; Calvieri S; Vezzoni G
    Cancer; 1997 Jun; 79(12):2354-60. PubMed ID: 9191523
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence.
    Schachter J; Brenner B; Fenig E; Yahav J; Marshak G; Sulkes A; Gutman H
    Oncol Rep; 1999; 6(6):1389-93. PubMed ID: 10523717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: the results of 5 years of follow-up.
    Elias EG; Zapas JL; Beam SL; Culpepper WJ
    Melanoma Res; 2007 Oct; 17(5):310-5. PubMed ID: 17885586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
    Lohmann CP; Kroher G; Bogenrieder T; Spiegel D; Preuner J
    Lancet; 1999 Apr; 353(9161):1326. PubMed ID: 10218534
    [No Abstract]   [Full Text] [Related]  

  • 53. High-dose adjuvant interferon therapy for melanoma.
    Licata AG
    Dermatol Nurs; 1998 Oct; 10(5):334-6. PubMed ID: 9873271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cutaneous necrosis due to interferon alpha in a patient with melanoma].
    Aguilar García G; Serrano Falcón C; Serrano Falcón Mdel M; Carmona MD; Linares Solano J; Serrano Ortega S
    Actas Dermosifiliogr; 2006 Oct; 97(8):539-42. PubMed ID: 17067536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current therapy of cutaneous melanoma.
    Mays SR; Nelson BR
    Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
    Kirkwood JM; Resnick GD; Cole BF
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
    Hillner BE
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S18-21. PubMed ID: 9849404
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
    McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
    Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of adjuvant therapy in cutaneous melanoma.
    Sondak VK
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):421-6. PubMed ID: 12113108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interferon-α-2b as an adjuvant therapy prolongs survival of patients with previously resected oral muscosal melanoma.
    Wang R; Jing G; Lv J; Song H; Li C; Wang X; Xia W; Wu Y; Ren G; Guo W
    Genet Mol Res; 2015 Oct; 14(4):11944-54. PubMed ID: 26505342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.